Antibiotics Market Research Report Information By Drug Class (Cephalosporins, Penicillin, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, Others), Spectrum of Activity (Broad-spectrum Antibiotic, Narrow-spectrum Antibiotic), Drug Origin (Natural, Semi-synthetic, Synthetic) and End-User (Hospitals & Clinics, Research Organizations, Others) – Forecast to 2032

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. Regulatory Framework

6. GLOBAL ANTIBIOTICS MARKET, BY DRUG CLASS

6.1. Overview

6.2. Cephalosporins

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Penicillin

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Fluoroquinolones

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Macrolides

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6. Carbapenem

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.7. Aminoglycosides

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.8. Sulfonamides

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.9. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY

7.1. Overview

7.2. Broad-Spectrum Antibiotic

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Narrow-Spectrum Antibiotic

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL ANTIBIOTICS MARKET, BY DRUG ORIGIN

8.1. Overview

8.2. Natural

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Semi-Synthetic

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Synthetic

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION

9.1. Overview

9.2. Oral

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3. Intravenous

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10. GLOBAL ANTIBIOTICS MARKET, BY END USER

10.1. Overview

10.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10.3. Research Organizations

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

11. GLOBAL ANTIBIOTICS MARKET, BY REGION

11.1. Overview

11.2. Americas

11.2.1. North America

11.2.1.1. US

11.2.1.2. Canada

11.2.2. Latin America

11.3. Europe

11.3.1. Western Europe

11.3.1.1. Germany

11.3.1.2. France

11.3.1.3. Italy

11.3.1.4. Spain

11.3.1.5. UK

11.3.1.6. Rest of Western Europe

11.3.2. Eastern Europe

11.4. Asia-Pacific

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. Australia

11.4.5. South Korea

11.4.6. Rest of Asia-Pacific

11.5. Middle East & Africa

11.5.1. Middle East

11.5.2. Africa

12. COMPANY LANDSCAPE

12.1.1. Overview

12.1.2. Competitive Analysis

13. COMPANY PROFILES

13.1. Pfizer Inc.

13.1.1. Company Overview

13.1.2. Product Overview

13.1.3. Financial Overview

13.1.4. Key Developments

13.1.5. SWOT Analysis

13.1.6. Key Strategies

13.2. Johnson & Johnson Services, Inc.

13.2.1. Company Overview

13.2.2. Product Overview

13.2.3. Financial Overview

13.2.4. Key Developments

13.2.5. SWOT Analysis

13.2.6. Key Strategies

13.3. Abbott Laboratories

13.3.1. Company Overview

13.3.2. Product Overview

13.3.3. Financial Overview

13.3.4. Key Developments

13.3.5. SWOT Analysis

13.3.6. Key Strategies

13.4. GlaxoSmithKline PLC

13.4.1. Company Overview

13.4.2. Product Overview

13.4.3. Financial Overview

13.4.4. Key Developments

13.4.5. SWOT Analysis

13.4.6. Key Strategies

13.5. Sanofi

13.5.1. Company Overview

13.5.2. Product Overview

13.5.3. Financial Overview

13.5.4. Key Developments

13.5.5. SWOT Analysis

13.5.6. Key Strategies

13.6. Novartis AG

13.6.1. Company Overview

13.6.2. Product Overview

13.6.3. Financial Overview

13.6.4. Key Developments

13.6.5. SWOT Analysis

13.6.6. Key Strategies

13.7. Bayer AG

13.7.1. Company Overview

13.7.2. Product Overview

13.7.3. Financial Overview

13.7.4. Key Developments

13.7.5. SWOT Analysis

13.7.6. Key Strategies

13.8. Bristol-Myers Squibb Company

13.8.1. Company Overview

13.8.2. Product Overview

13.8.3. Financial Overview

13.8.4. Key Developments

13.8.5. SWOT Analysis

13.8.6. Key Strategies

13.9. Eli Lilly and Company

13.9.1. Company Overview

13.9.2. Product Overview

13.9.3. Financial Overview

13.9.4. Key Developments

13.9.5. SWOT Analysis

13.9.6. Key Strategies

13.10. Astellas Pharma Inc.

13.10.1. Company Overview

13.10.2. Product Overview

13.10.3. Financial Overview

13.10.4. Key Developments

13.10.5. SWOT Analysis

13.10.6. Key Strategies

13.11. Merck & Co., Inc.

13.11.1. Company Overview

13.11.2. Product Overview

13.11.3. Financial Overview

13.11.4. Key Developments

13.11.5. SWOT Analysis

13.11.6. Key Strategies

13.12. F. Hoffmann-La Roche Ltd

13.12.1. Company Overview

13.12.2. Product Overview

13.12.3. Financial Overview

13.12.4. Key Developments

13.12.5. SWOT Analysis

13.12.6. Key Strategies

14. APPENDIX

14.1. References

14.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL ANTIBIOTICS MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL ANTIBIOTICS MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL ANTIBIOTICS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 7 GLOBAL ANTIBIOTICS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 8 GLOBAL ANTIBIOTICS MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: ANTIBIOTICS, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 10 NORTH AMERICA: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2020-2027 (USD MILLION)

TABLE 11 NORTH AMERICA: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2020-2027 (USD MILLION)

TABLE 12 NORTH AMERICA: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 13 NORTH AMERICA: ANTIBIOTICS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 14 US: ANTIBIOTICS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 15 US: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2020-2027 (USD MILLION)

TABLE 16 US: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2020-2027 (USD MILLION)

TABLE 17 US: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 18 US: ANTIBIOTICS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 19 CANADA: ANTIBIOTICS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 20 CANADA: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2020-2027 (USD MILLION)

TABLE 21 CANADA: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2020-2027 (USD MILLION)

TABLE 22 CANADA: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 23 CANADA: ANTIBIOTICS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 24 LATIN AMERICA: ANTIBIOTICS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 25 LATIN AMERICA: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2020-2027 (USD MILLION)

TABLE 26 LATIN AMERICA: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2020-2027 (USD MILLION)

TABLE 27 LATIN AMERICA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 28 LATIN AMERICA ANTIBIOTICS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 29 EUROPE: ANTIBIOTICS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 30 EUROPE ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2020-2027 (USD MILLION)

TABLE 31 EUROPE ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2020-2027 (USD MILLION)

TABLE 32 EUROPE: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 33 EUROPE: ANTIBIOTICS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 34 WESTERN EUROPE: ANTIBIOTICS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 35 WESTERN EUROPE: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2020-2027 (USD MILLION)

TABLE 36 WESTERN EUROPE: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2020-2027 (USD MILLION)

TABLE 37 WESTERN EUROPE: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 38 WESTERN EUROPE: ANTIBIOTICS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 39 EASTERN EUROPE ANTIBIOTICS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 40 EASTERN EUROPE: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2020-2027 (USD MILLION)

TABLE 41 EASTERN EUROPE: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2020-2027 (USD MILLION)

TABLE 42 EASTERN EUROPE: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 43 EASTERN EUROPE: ANTIBIOTICS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 44 ASIA-PACIFIC: ANTIBIOTICS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 45 ASIA-PACIFIC: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2020-2027 (USD MILLION)

TABLE 46 ASIA-PACIFIC: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2020-2027 (USD MILLION)

TABLE 47 ASIA-PACIFIC: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 48 ASIA-PACIFIC: ANTIBIOTICS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA: ANTIBIOTICS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2020-2027 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2020-2027 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA ANTIBIOTICS MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ANTIBIOTICS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ANTIBIOTICS MARKET

FIGURE 4 GLOBAL ANTIBIOTICS MARKET SHARE, BY DRUG CLASS, 2020 (%)

FIGURE 5 GLOBAL ANTIBIOTICS MARKET SHARE, BY SPECTRUM OF ACTIVITY, 2020 (%)

FIGURE 6 GLOBAL ANTIBIOTICS MARKET SHARE, BY DRUG ORIGIN, 2020 (%)

FIGURE 7 GLOBAL ANTIBIOTICS MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2020 (%)

FIGURE 8 GLOBAL ANTIBIOTICS MARKET SHARE, BY END USER (%)

FIGURE 9 GLOBAL ANTIBIOTICS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 AMERICAS: ANTIBIOTICS MARKET SHARE BY REGION, 2020 (%)

FIGURE 11 NORTH AMERICA: ANTIBIOTICS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 EUROPE: ANTIBIOTICS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 13 WESTERN EUROPE: ANTIBIOTICS OR MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 ASIA-PACIFIC: ANTIBIOTICS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 15 MIDDLE EAST & AFRICA: ANTIBIOTICS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 16 GLOBAL ANTIBIOTICS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 17 PFIZER INC.: KEY FINANCIALS

FIGURE 18 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 19 PFIZER INC.: REGIONAL REVENUE

FIGURE 20 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS

FIGURE 21 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE

FIGURE 22 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE

FIGURE 23 ABBOTT LABORATORIES: KEY FINANCIALS

FIGURE 24 ABBOTT LABORATORIES: SEGMENTAL REVENUE

FIGURE 25 ABBOTT LABORATORIES: REGIONAL REVENUE

FIGURE 26 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 27 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 28 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 29 SANOFI: KEY FINANCIALS

FIGURE 30 SANOFI: SEGMENTAL REVENUE

FIGURE 31 SANOFI: REGIONAL REVENUE

FIGURE 32 NOVARTIS AG: KEY FINANCIALS

FIGURE 33 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 34 NOVARTIS AG: REGIONAL REVENUE

FIGURE 35 BAYER AG: KEY FINANCIALS

FIGURE 36 BAYER AG: SEGMENTAL REVENUE

FIGURE 37 BAYER AG: REGIONAL REVENUE

FIGURE 38 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS

FIGURE 39 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE

FIGURE 40 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE

FIGURE 41 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 42 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 43 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 44 ASTELLAS PHARMA INC..: KEY FINANCIALS

FIGURE 45 ASTELLAS PHARMA INC.: SEGMENTAL REVENUE

FIGURE 46 ASTELLAS PHARMA INC.: REGIONAL REVENUE

FIGURE 47 MERCK & CO., INC.: KEY FINANCIALS

FIGURE 48 MERCK & CO., INC.: SEGMENTAL REVENUE

FIGURE 49 MERCK & CO., INC.: REGIONAL REVENUE

FIGURE 50 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

FIGURE 51 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 52 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE